CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. TOP PLAYER POSITIONING, 2016
3.4. PORTERS FIVE FORCES ANALYSIS
3.5. REGULATIONS
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Increase in demand for safe and non-invasive procedures
3.6.1.2. Surge in prevalence of cancer worldwide.
3.6.1.3. Advantages of liquid biopsy tests

3.6.2. Restraints

3.6.2.1. Limitations associated with liquid biopsy testing
3.6.2.2. Lack of awareness in developing in underdeveloped regions

3.6.3. Opportunities

3.6.3.1. Rise in pre-screening programs for cancer detection using liquid biopsy
3.6.3.2. Untapped potential of emerging markets

CHAPTER 4 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. KITS & REAGENTS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. PLATFORMS & INSTRUMENTS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. SERVICES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. CIRCULATING TUMOR CELL (CTC)

5.2.1. Market size and forecast

5.3. CIRCULATING TUMOR DNA (CTDNA)

5.3.1. Market size and forecast

5.4. EXTRACELLULAR VESICLES (EVS)

5.4.1. Market size and forecast

5.5. OTHER BIOMARKERS

5.5.1. Market size and forecast

CHAPTER 6 LIQUID BIOPSY MARKET, BY CANCER TYPE

6.1. OVERVIEW

6.1.1. Market Size and Forecast

6.2. LUNG CANCER

6.2.1. Market size and forecast

6.3. BREAST CANCER

6.3.1. Market size and forecast

6.4. COLORECTAL CANCER

6.4.1. Market size and forecast

6.5. PROSTATE CANCER

6.5.1. Market size and forecast

6.6. LIVER CANCER

6.6.1. Market size and forecast

6.7. OTHER CANCERS

6.7.1. Market size and forecast

CHAPTER 7 LIQUID BIOPSY MARKET, BY END USER

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. HOSPITAL AND LABORATORY

7.2.1. Market size and forecast

7.3. GOVERNMENT AND ACADEMIC RESEARCH CENTERS

7.3.1. Market size and forecast

CHAPTER 8 LIQUID BIOPSY MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.2.3.1. U.S. market size and forecast
8.2.3.2. Canada market size and forecast
8.2.3.3. Mexico market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.3.3.1. Germany market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. UK market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Rest of Europe market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. Australia market size and forecast
8.4.3.4. India market size and forecast
8.4.3.5. South Korea market size and forecast
8.4.3.6. Taiwan market size and forecast
8.4.3.7. India market size and forecast
8.4.3.8. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast

8.5.3.1. Brazil market size and forecast
8.5.3.2. Turkey market size and forecast
8.5.3.3. Saudi Arabia market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1. BIOCEPT, INC.

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance

9.2. QIAGEN N.V.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance

9.3. F. HOFFMANN-LA ROCHE AG

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance

9.4. BIO-RAD LABORATORIES INC.

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance

9.5. MYRIAD GENETICS

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance

9.6. JANSSEN DIAGNOSTICS, LLC.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance

9.7. TROVAGENE INC.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance

9.8. GUARDIANT HEALTH, INC.

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance

9.9. GRAIL

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance

9.10. MDX HEALTH SA

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance